Holen Sie sich die Stockscreener-App
578.61
2.29%
-13.55
Handel nachbörslich:
578.61
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TMO?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$592.16
Offen:
$581.73
24-Stunden-Volumen:
3.76M
Relative Volume:
1.98
Marktkapitalisierung:
$217.39B
Einnahmen:
$43.74B
Nettoeinkommen (Verlust:
$6.58B
KGV:
33.43
EPS:
17.3072
Netto-Cashflow:
$6.11B
1W Leistung:
-7.57%
1M Leistung:
-0.83%
6M Leistung:
+21.23%
1J Leistung:
-4.64%
1-Tages-Spanne:
$574.23
$585.95
1-Wochen-Bereich:
$572.21
$633.65
52-Wochen-Spanne:
$385.46
$643.99
Thermo Fisher Scientific Inc Stock (TMO) Company Profile
Firmenname
Thermo Fisher Scientific Inc
Sektor
Branche
Telefon
(781) 622-1000
Adresse
168 THIRD AVENUE, WALTHAM, MA
Vergleichen Sie TMO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TMO
Thermo Fisher Scientific Inc
|
578.61 | 222.48B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
218.89 | 155.25B | 24.57B | 3.60B | 5.25B | 5.0475 |
|
IDXX
Idexx Laboratories Inc
|
670.46 | 54.04B | 4.17B | 1.03B | 940.22M | 12.61 |
|
IQV
Iqvia Holdings Inc
|
230.15 | 40.13B | 15.90B | 1.28B | 2.21B | 7.2842 |
|
A
Agilent Technologies Inc
|
133.85 | 37.78B | 6.95B | 1.30B | 1.15B | 4.5696 |
Thermo Fisher Scientific Inc Stock (TMO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-11 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-12-09 | Eingeleitet | Goldman | Buy |
| 2025-12-08 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2025-12-02 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-12-01 | Hochstufung | HSBC Securities | Hold → Buy |
| 2025-09-11 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2025-08-19 | Eingeleitet | William Blair | Outperform |
| 2025-07-24 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-07-11 | Hochstufung | Scotiabank | Sector Perform → Sector Outperform |
| 2025-07-09 | Herabstufung | UBS | Buy → Neutral |
| 2025-01-10 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2024-12-23 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-10-14 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-10-01 | Eingeleitet | Stephens | Overweight |
| 2024-08-28 | Eingeleitet | Wells Fargo | Overweight |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-03-18 | Fortgesetzt | Citigroup | Neutral |
| 2024-01-24 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-01-08 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2023-12-18 | Eingeleitet | HSBC Securities | Buy |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-10-26 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2023-10-25 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2023-09-28 | Eingeleitet | Bernstein | Outperform |
| 2023-09-06 | Fortgesetzt | Citigroup | Buy |
| 2023-07-19 | Eingeleitet | Raymond James | Outperform |
| 2023-07-19 | Bestätigt | Robert W. Baird | Outperform |
| 2023-07-13 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2023-04-04 | Bestätigt | Barclays | Overweight |
| 2022-12-14 | Eingeleitet | Deutsche Bank | Buy |
| 2022-12-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-10-27 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2022-08-25 | Eingeleitet | Credit Suisse | Neutral |
| 2022-04-25 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2022-01-26 | Fortgesetzt | Barclays | Overweight |
| 2021-10-20 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-07-16 | Eingeleitet | The Benchmark Company | Buy |
| 2021-03-18 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-03-03 | Eingeleitet | Barclays | Overweight |
| 2021-01-08 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-12-02 | Eingeleitet | Goldman | Buy |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2020-09-30 | Eingeleitet | Atlantic Equities | Overweight |
| 2020-09-14 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-08-20 | Fortgesetzt | JP Morgan | Overweight |
| 2020-07-15 | Hochstufung | Cleveland Research | Neutral → Buy |
| 2020-07-07 | Bestätigt | Needham | Buy |
| 2020-04-23 | Bestätigt | Needham | Buy |
| 2020-01-31 | Bestätigt | Needham | Buy |
| 2020-01-22 | Eingeleitet | Credit Suisse | Neutral |
| 2020-01-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-11-15 | Eingeleitet | Stifel | Buy |
| 2019-07-25 | Bestätigt | Needham | Buy |
| 2019-07-16 | Herabstufung | Needham | Strong Buy → Buy |
| 2019-05-30 | Eingeleitet | Wolfe Research | Outperform |
| 2019-05-23 | Bestätigt | Needham | Strong Buy |
| 2019-04-22 | Bestätigt | Needham | Strong Buy |
| 2019-04-16 | Bestätigt | BofA/Merrill | Buy |
Alle ansehen
Thermo Fisher Scientific Inc Aktie (TMO) Neueste Nachrichten
Thermo Fisher to close Mass. facility, lay off over 100 workers - The Business Journals
Thermo Fisher Scientific (TMO): Citigroup Raises Price Target, M - GuruFocus
Thermo Fisher Scientific (TMO): Analyst Ratings Update for Janua - GuruFocus
UBS Adjusts Price Target on Thermo Fisher Scientific to $615 From $590, Maintains Neutral Rating - marketscreener.com
Thermo Fisher stock rating reiterated at Buy by Stifel on solid 2025 finish - Investing.com
Thermo Fisher Scientific Inc. (NYSE:TMO) Q4 2025 Earnings Call Transcript - Insider Monkey
Thermo Fisher: The Market Is Missing The Point, This Pullback Is A Buy (Rating Update) - Seeking Alpha
JPMorgan Adjusts Price Target on Thermo Fisher Scientific to $710 From $675, Maintains Overweight Rating - marketscreener.com
Rothschild & Co Redburn Adjusts PT on Thermo Fisher Scientific to $620 From $575, Maintains Buy Rating - marketscreener.com
Chromatography Research Report 2026 - GlobeNewswire Inc.
Thermo Fisher Scientific Q4 Earnings Call Highlights - Yahoo Finance
Thermo Fisher Scientific and NVIDIA Partner to Advance Laboratory AI Automation - Lab Manager
Thermo Fisher Scientific (TMO) Margin Improvement Challenges Long Term Earnings Decline Narrative - simplywall.st
Thermo Fisher stock slides on 2026 profit outlook as research funding cuts bite — what’s next for TMO - TechStock²
Thermo Fisher Scientific (TMO) Reports Strong Q4 2025 Performanc - GuruFocus
Thermo Fisher forecasts 2026 profit below estimates on research funding cuts - marketscreener.com
Up and Down Morning for Thermo Fisher Scientific - WFMZ.com
Thermo Fisher Scientific Inc (TMO) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Thermo Fisher (TMO) stock drops after 2026 profit outlook misses on research funding cuts - TechStock²
Baird Lifts Thermo Fisher Scientific Price Target to $653 From $645 - marketscreener.com
JPMorgan Raises Thermo Fisher Scientific Price Target to $710 From $675 - marketscreener.com
Thermo Fisher Scientific Discloses How Much Clario Deal Could Add To Its EPS - Benzinga
Thermo Fisher Scientific Reports Fourth Quarter and Full Year 2025 Results - BioSpace
Thermo Fisher stock slides on cautious profit guidance - Proactive financial news
AI for investors - MLQ.ai
Thermo Fisher (TMO) Q4 2025 Earnings Transcript - AOL.com
Thermo Fisher Scientific: Resilient Organic Growth and Stabilizing End Markets Support Sustained Buy Rating - TipRanks
Thermo Fisher Scientific (TMO) Projects Revenue Growth for FY26 - GuruFocus
Thermo Fisher (TMO) Reports Q4 Earnings: What Key Metrics Have to Say - Nasdaq
Thermo Fisher slips after issuing 2026 outlook (update) - Seeking Alpha
Thermo Fisher and NVIDIA Partner to Expand AI Driven Laboratory Automation - Chromatography Online
Thermo Fisher beats quarterly results estimates on demand for tools from pharma clients - WKZO
Thermo Fisher shares rise after Q4 results beat forecasts - MSN
Thermo Fisher Scientific (TMO) Surpasses Q4 2025 Earnings Expectations - GuruFocus
Thermo Fisher Scientific Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Thermo Fisher (NYSE:TMO) Posts Better-Than-Expected Sales In Q4 CY2025 - Finviz
Thermo Fisher Scientific (TMO) Exceeds Q4 2025 Expectations - GuruFocus
Thermo Fisher Scientific (TMO) Exceeds Q4 Earnings Expectations - GuruFocus
Thermo Fisher Scientific (TMO) Beats Q4 Earnings and Revenue Estimates - Yahoo Finance UK
Thermo Fisher Scientific Q4 Adjusted Earnings, Revenue Rise - marketscreener.com
Thermo Fisher (TMO) Reports Strong Q4 Revenue Exceeding Expectat - GuruFocus
Thermo Fisher 4Q Profit Rises as Biopharma Spending Rebounds - marketscreener.com
Thermo Fisher: Q4 Earnings Snapshot - kare11.com
Thermo Fisher Q4 earnings: revenue and EPS top estimates - grafa.com
Thermo Fisher Scientific (TMO) Surpasses Q4 2025 Expectations - Tokenist
Thermo Fisher beats fourth-quarter expectations, shares climb By Investing.com - Investing.com Canada
Thermo Fisher Scientific Announces Increase In Q4 Bottom Line - Nasdaq
Thermo Fisher Scientific earnings beat by $0.12, revenue topped estimates - Investing.com Nigeria
Thermo Fisher (TMO) stock slides into earnings — here’s what Wall Street is watching - TechStock²
WilmerHale-Advised Thermo Fisher Bond Offering Wins GlobalCapital’s Swiss Franc Bond of the Year Award - WilmerHale
A Glimpse of Thermo Fisher Scientific's Earnings Potential - Benzinga
Finanzdaten der Thermo Fisher Scientific Inc-Aktie (TMO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.33%
0.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):